Articles

This article reviews a presentation by Kathryn Aikin of DDMAC/FDA in which she disclosed preliminary results from the FDA's Physician Survey, which looked at the impact of DTC advertising on the doctor-patient relationship

Attending conferences like the recent Pharmaceutical Marketing Global Summit provides tidbits of information about how pharma marketing practices need to evolve. Although the advice from one expert often conflicts with that of another, and sometimes the advice is self-serving, some suggestions seem to ring true and have universal support.

There are powerful lobbyists, including employers, insurers, AARP, and Public Citizen, with an anti-DTC agenda in Washington. The criticism takes many forms - increases in drug prices, increase in inappropriate prescribing, etc. Republicans have gained control, but some committee chairs are DTC critics.

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

What's the connection between the effectiveness of DTC advertising, patient-level data vs. physician-level data, and out-of-the-box marketing? Adoption of these new techniques and data sources by pharmaceutical marketers depends on good education, vendor cooperation, and success stories to prove that the effort is worth it

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

Although most experts agree that pharmaceutical companies are not covered entities under HIPAA, this does not mean that pharma marketers should not worry about it. Pharma needs to realize that HIPAA will have a significant impact on the commercial side of their business. One effect, for example, will be HIPAA's influence on state medical privacy laws, which may directly affect pharmaceutical companies and their advertising and marketing partners. This article is a summary of a presentation by Brent Saunders, Partner, PricewaterhouseCoopers. The presentation was made at the Pharmaceutical Regulatory & Compliance Congress and Best Practices Forum held at the Philadelphia Marriott Hotel on November 13-15, 2002.

Anyone who is even a casual reader of Pharma Marketing News knows that we support consumers' right to privacy and believe that pharmaceutical marketers need to beef up their privacy policies if they hope to improve consumer trust. So it may surprise you when we say that a new Texas privacy law goes too far in its apparent zeal to protect patients' privacy. In fact, we believe that this law's real purpose is to limit the ability of pharmaceutical companies and their agents to communicate product information directly to consumers in Texas. The privacy law we talking about is the Texas Medical Privacy Act (SB 11). SB 11 is known in some quarters as 'super HIPAA' because it applies super-stringent HIPAA-like privacy regulations to pharmaceutical companies, their advertising/ marketing agencies and other entities - even individuals. A covered entity under SB 11 is any person who assembles, collects, analyses, uses, evaluates, stores, or transmits protected health information. The law becomes effective in Texas September 1, 2003.